Wall Street brokerages expect that Medidata Solutions Inc (NASDAQ:MDSO) will post $0.36 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Medidata Solutions’ earnings, with the lowest EPS estimate coming in at $0.29 and the highest estimate coming in at $0.46. Medidata Solutions posted earnings of $0.41 per share in the same quarter last year, which would suggest a negative year over year growth rate of 12.2%. The business is scheduled to issue its next quarterly earnings report on Thursday, February 14th.

According to Zacks, analysts expect that Medidata Solutions will report full year earnings of $1.63 per share for the current fiscal year, with EPS estimates ranging from $1.54 to $1.72. For the next financial year, analysts forecast that the business will report earnings of $1.85 per share, with EPS estimates ranging from $1.67 to $2.00. Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Medidata Solutions.

Medidata Solutions (NASDAQ:MDSO) last posted its earnings results on Thursday, October 18th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.06. Medidata Solutions had a net margin of 8.43% and a return on equity of 10.70%. The firm had revenue of $163.41 million for the quarter, compared to the consensus estimate of $162.09 million. During the same period in the previous year, the firm posted $0.33 EPS. The business’s quarterly revenue was up 17.6% on a year-over-year basis.

A number of analysts have recently weighed in on the stock. ValuEngine upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. JPMorgan Chase & Co. reduced their target price on shares of Medidata Solutions to $74.00 and set a “neutral” rating on the stock in a report on Friday, October 19th. Royal Bank of Canada set a $86.00 target price on shares of Medidata Solutions and gave the stock a “buy” rating in a report on Friday, October 19th. Piper Jaffray Companies reduced their target price on shares of Medidata Solutions from $96.00 to $93.00 in a report on Thursday, October 18th. Finally, Zacks Investment Research downgraded shares of Medidata Solutions from a “hold” rating to a “sell” rating in a report on Tuesday, October 16th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $84.64.

Medidata Solutions stock opened at $72.45 on Friday. Medidata Solutions has a twelve month low of $59.60 and a twelve month high of $88.87. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.52 and a current ratio of 2.52. The stock has a market capitalization of $4.43 billion, a PE ratio of 85.24, a price-to-earnings-growth ratio of 4.28 and a beta of 1.30.

In related news, EVP Michael I. Otner sold 7,030 shares of Medidata Solutions stock in a transaction dated Tuesday, October 23rd. The shares were sold at an average price of $69.40, for a total transaction of $487,882.00. Following the completion of the transaction, the executive vice president now directly owns 62,548 shares of the company’s stock, valued at approximately $4,340,831.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.70% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in MDSO. Man Group plc purchased a new stake in Medidata Solutions in the 3rd quarter valued at about $205,000. Quantbot Technologies LP purchased a new stake in Medidata Solutions in the 3rd quarter valued at about $229,000. World Asset Management Inc purchased a new stake in Medidata Solutions in the 2nd quarter valued at about $235,000. Zeke Capital Advisors LLC purchased a new stake in Medidata Solutions in the 2nd quarter valued at about $239,000. Finally, First Republic Investment Management Inc. purchased a new stake in Medidata Solutions in the 2nd quarter valued at about $242,000.

Medidata Solutions Company Profile

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Read More: The Role of a Fiduciary and Individual Investors

Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.